Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2319833121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Dan Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853. Hauptthemen laut MEDLINE: Colitis, Intestinal Mucosa, Sirtuin 2. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCRR NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Sirt2 is a nicotinamide adenine dinucleotide (NAD + )-dependent protein lysine deacylase that can remove both acetyl group and long-chain fatty acyl groups from lysine residues of many proteins. It was reported to affect inflammatory bowel disease (IBD) symptoms in a mouse model. However, conflicting roles were reported, with genetic knockout aggravating while pharmacological inhibition alleviating IBD symptoms. These seemingly conflicting reports cause confusion and deter further efforts in developing Sirt2 inhibitors as a potential treatment strategy for IBD. We investigated these conflicting reports and elucidated the role of Sirt2 in the mouse model of IBD. We essentially replicated these conflicting results and confirmed that Sirt2 inhibitors’ protective effect is not through off-targets as two very different Sirt2 inhibitors (TM and AGK2) showed similar protection in the IBD mouse model. We believe that the differential effects of inhibitors and knockout are due to the fact that the Sirt2 inhibitors only inhibit some but not all the activities of Sirt2. This hypothesis is confirmed by the observation that a PROTAC degrader of Sirt2 did not protect mice in the IBD model, similar to Sirt2 knockout. Our study provides an interesting example where genetic knockout and pharmacological inhibition do not align and emphasizes the importance of developing substrate-dependent inhibitors. Importantly, we showed that the effect of Sirt2 inhibition in IBD is through regulating the gut epithelium barrier by inhibiting Arf6-mediated endocytosis of E-cadherin, a protein important for the intestinal epithelial integrity. This mechanistic understanding further supports Sirt2 as a promising therapeutic target for treating IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853.
- HHMI, Cornell University, Ithaca, NY 14853.
- Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853.
ORCID-Profile: Dan Hou, Tao Yu, Hening Lin
Förderung
- NIAID NIH HHS
- NCRR NIH HHS
- Howard Hughes Medical Institute
- HHS | National Institutes of Health
Zitieren
APA
Hou, D., Yu, T., Lu, X., Hong, J. Y., Yang, M., Zi, Y., Ho, T. T., & Lin, H. (2024). Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2319833121
Vancouver
Hou D, Yu T, Lu X, Hong JY, Yang M, Zi Y, et al. Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2319833121
BibTeX
@article{Hou2024,
author = {Hou, Dan and Yu, Tao and Lu, Xuan and Hong, Jun Young and Yang, Min and Zi, Yanlin and Ho, Thanh Tu and Lin, Hening},
title = {Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2319833121}
}
EUVIMED